Kyverna Therapeutics (KYTX) director Cohen received 5,093 shares

Insider transactions reported

Fred E Cohen (director at Kyverna Therapeutics Inc., KYTX) reported that they received 5,093 shares on May 27, 2026. After these transactions the filing shows 21,727 shares held directly.

Reporting person

Cohen Fred E

Options and other derivatives

Holdings before and after

• Common Stock: 16,634 to 21,727 direct
• Stock Option (right to buy): 0 to 20,582 direct

Other positions listed

• Common Stock: 4,523,924 indirect, See Footnote

Footnotes from the filing

1. 1. Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
2. 2. All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
3. 3. Shares held directly by Vida Ventures, LLC ( Vida ). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any.

Transaction codes in this filing

Grant or award:

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ